Tuesday, June 14, 2016

BRIEF-Celator pharmaceuticals announces positive results in patients with flt3 mutation from phase 3 trial in high-risk acute myeloid leukemia

* Data from AML patients with a flt3 mutation demonstrated

vyxeos had a statistically significant improvement in induction

response rate

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)